Sedation practices in pediatric patients with acute lymphoblastic leukemia

被引:9
|
作者
Nugent, Bethany D. [1 ]
Davis, Peter J. [1 ,2 ]
Noll, Robert B. [1 ]
Tersak, Jean M. [1 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] UPMC, Dept Anesthesiol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA
[3] UPMC, Div Pediat Hematol Oncol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA
关键词
acute lymphoblastic leukemia; anesthesia; late effects of cancer treatment; lumbar puncture; neurotoxicity of therapy; NEUROCOGNITIVE OUTCOMES; GENERAL-ANESTHESIA; PROPOFOL; EXPOSURE; SURVIVORS; NEURONS; CHEMOTHERAPY; OLIGODENDROCYTES; NEUROTOXICITY; VASODILATION;
D O I
10.1002/pbc.28037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The 5-year survival for pediatric acute lymphoblastic leukemia (ALL) is greater than 90%. One late effect of pediatric ALL associated with numerous long-term difficulties is neurocognitive deficits. The experience at our institution, as well as conversations with oncologists at other institutions, suggests an increase in the use of sedation during lumbar punctures (LPs) for treatment of pediatric ALL. Among the most common Children's Oncology Group (COG) ALL protocols, approximately 30 LPs are performed over 2-3 years. Studies in animals reveal that sedation drugs may harm the developing brain. Gaps in knowledge exist regarding their use in children, particularly repeated exposures. The purpose of this study is to summarize sedation practices for LPs related to the treatment of ALL at COG institutions. Methods Responsible Individuals (RIs) of the Cancer Control Committee of COG were invited to complete an internet-based survey about sedation practices at their institutions. Results Surveys were sent to 103 RIs with a 62% response rate (N = 64). A combined 2018 new patients with ALL were seen each year (mean = 31.5, range = 3-110) at the participating institutions. The majority (96%) of children with ALL received sedation for LPs. While there was considerable variability across institutions in the type of sedation given, the most common was propofol alone (n = 36, 56%). Conclusions A substantial number of children with ALL receive sedation for LPs; however, there is variation in the medication used. Better understanding of sedation practices in children with ALL may inform future research to investigate which methods are the safest, with an emphasis on long-term neurocognitive late effects.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Assessment of the Prevalence of Infections in Pediatric Patients With Acute Lymphoblastic Leukemia
    Nair, Arun
    Elballushi, Ruaa
    Joshi, Riecha
    Anjanappa, Sanvithi
    Akter, Maksuda
    Arif, Sehrish
    Rehman, Sana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [22] Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients
    B Maecker
    D Mougiakakos
    M Zimmermann
    M Behrens
    S Hollander
    A Schrauder
    M Schrappe
    K Welte
    C Klein
    Leukemia, 2006, 20 : 645 - 649
  • [23] Gaps in Insurance Coverage for Pediatric Patients With Acute Lymphoblastic Leukemia
    Smits-Seemann, Rochelle R.
    Kaul, Sapna
    Hersh, Aimee O.
    Fluchel, Mark N.
    Boucher, Kenneth M.
    Kirchhoff, Anne C.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (02) : 175 - +
  • [24] The hypermethylome of pediatric acute lymphoblastic leukemia
    Davidsson, Josef
    Lilljebjorn, Henrik
    Andersson, Anna
    Veerla, Srinivas
    Heldrup, Jesper
    Behrendtz, Mikael
    Fioretos, Thoas
    Johansson, Bertil
    CELLULAR ONCOLOGY, 2008, 30 (03) : 252 - 252
  • [25] Treatment of Pediatric Acute Lymphoblastic Leukemia
    Cooper, Stacy L.
    Brown, Patrick A.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2015, 62 (01) : 61 - +
  • [26] Epigenetics in pediatric acute lymphoblastic leukemia
    Nordlund, Jessica
    Syvanen, Ann-Christine
    SEMINARS IN CANCER BIOLOGY, 2018, 51 : 129 - 138
  • [27] Immunotherapy in pediatric acute lymphoblastic leukemia
    Hiroto Inaba
    Ching-Hon Pui
    Cancer and Metastasis Reviews, 2019, 38 : 595 - 610
  • [28] Infection and pediatric acute lymphoblastic leukemia
    Ma, Xiaomei
    Urayama, Kevin
    Chang, Jeffrey
    Wiemels, Joseph L.
    Buffler, Patricia A.
    BLOOD CELLS MOLECULES AND DISEASES, 2009, 42 (02) : 117 - 120
  • [29] Immunotherapy in pediatric acute lymphoblastic leukemia
    Inaba, Hiroto
    Pui, Ching-Hon
    CANCER AND METASTASIS REVIEWS, 2019, 38 (04) : 595 - 610
  • [30] PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Anak, S. Sema
    LEUKEMIA RESEARCH, 2014, 38 : S22 - S23